Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 525-533 , July 2009

Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate

  • Alessandra Banzato

      Affiliations

    • Department of Oncology and Surgical Sciences, University of Padua, I-35128 Padova, Italy
    • ,
  • Maria Rondina

      Affiliations

    • Department of Oncology and Surgical Sciences, University of Padua, I-35128 Padova, Italy
    • ,
  • Laura Meléndez-Alafort

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, Padova, Italy
    • ,
  • Elena Zangoni

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, Padova, Italy
    • ,
  • Anna Nadali

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, Padova, Italy
    • ,
  • Davide Renier

      Affiliations

    • Fidia Farmaceutici, Abano Terme, Italy
    • ,
  • Giuliano Moschini

      Affiliations

    • Department of Physics, University of Padua, Padova, Italy
    • ,
  • Ulderico Mazzi

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, Padova, Italy
    • ,
  • Paola Zanovello

      Affiliations

    • Department of Oncology and Surgical Sciences, University of Padua, I-35128 Padova, Italy
    • Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy
    • ,
  • Antonio Rosato

      Affiliations

    • Department of Oncology and Surgical Sciences, University of Padua, I-35128 Padova, Italy
    • Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy
    • Corresponding Author InformationCorresponding author. Department of Oncology and Surgical Sciences, University of Padua, I-35128 Padova, Italy. Tel.: +39 49 8215800/8215858; fax: +1 39 49 8072854.

Received 3 February 2008 ,Revised 6 February 2009 ,Accepted 18 February 2009.

References 

  1. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol. 2007;25:209–216
  2. Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res. 2007;24:1172–1185
  3. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2:689–700
  4. Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol. 2007;152:38–52
  5. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst. 2006;98:580–598
  6. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res. 2007;96:213–268
  7. Mehvar R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives. Curr Pharm Biotechnol. 2003;4:283–302
  8. Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorgan Med Chem. 2005;13:5043–5054
  9. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688–701
  10. Vicent MJ, Dieudonné L, Carbajo RJ, Pineda-Lucena A. Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin Drug Deliv. 2008;5:593–614
  11. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409–419
  12. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528–539
  13. Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 2005;12:327–342
  14. Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–231
  15. Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A. 2004;101:18081–18086
  16. Weigel JA, Raymond RC, McGary C, Singh A, Weigel PH. A blocking antibody to the hyaluronan receptor for endocytosis (HARE) inhibits hyaluronan clearance by perfused liver. J Biol Chem. 2003;278:9808–9812
  17. Greiner J, Ringhoffer M, Taniguchi M, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol. 2002;30:1029–1035
  18. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer. 2003;106:224–231
  19. Makrydimas G, Zagorianakou N, Zagorianakou P, Agnantis NJ. CD44 family and gynaecological cancer. In Vivo. 2003;17:633–640
  20. Platt VM, Szoka FC. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008;5:474–486
  21. Rosato A, Banzato A, De Luca G, Renier D, Bettella F, Pagano C, et al. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol. 2006;24:207–215
  22. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263–1268
  23. Cormio G, Di Vagno G, Melilli GA, Cazzolla A, DiGesù G, Carriero C, et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother. 1999;11:407–409
  24. Meléndez-Alafort L, Riondato M, Nadali A, Banzato A, Camporese D, Boccaccio P, et al. Bioavailability of 99mTc-HA-paclitaxel complex [99mTc-ONCOFID-P] in mice using four different administration routes. J Label Compd Radiopharm. 2006;49:939–950
  25. Davison A, DePamphilis BV, Jones AG, Franklin KJ, Lock CJL. Synthesis and characterization of complexes containing the bis(1, 2-diolato)-oxotechnetium(V) core. Inorg Chim Acta. 1987;128:161–167
  26. Uzunov N, Bello M, Boccaccio P, Moschini G, Baldazzi G, Bollini D, et al. Performance measurements of a high-spatial-resolution YAP camera. Phys Med Biol. 2005;50:N11–N21
  27. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998;58:2404–2409
  28. Li C, Price JE, Milas L, Hunter NR, Cabral F, Stephens LC, et al Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res. 1999;5:891–897
  29. Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res. 2000;60:4146–4151
  30. Auzenne E, Donato NJ, Li C, Leroux E, Price RE, Farquhar D, et al. Superior therapeutic profile of poly-l-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res. 2002;8:573–581
  31. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs. 1996;7:78–86
  32. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med. 2005;46:1866–1871
  33. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JLS. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res. 2007;24:1691–1701
  34. Cao O, Li ZB, Chen K, Wu Z, He L, Neamati N, et al. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer. Eur J Nucl Med Mol Imaging. 2008;35:1489–1498
  35. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist. 2008;13:248–260
  36. Lindqvist U, Westerberg G, Bergstrom M, Torsteindottir I, Gustafson S, Sundin A, et al. [11C]Hyaluronan uptake with positron emission tomography in liver disease. Eur J Clin Invest. 2000;30:600–607
  37. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Zerrouk N, Caramella C. Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J Pharm Pharmacol. 2004;56:1083–1090
  38. Ross JS, del Rosario AD, Bui HX, Kallakury BV, Okby NT, Figge J. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol. 1996;9:854–860
  39. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumors and their relation to prognosis during a long-term follow-up. J Pathol. 1998;186:157–164
  40. Kong QY, Liu J, Chen XY, Wang XW, Sun Y, Li H. Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep. 2003;10:51–55
  41. Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1–20
  42. Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol. 2007;25:2867–2872
  43. Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res. 2008;14:3598–3606
  44. Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis B, et al. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. Anticancer Res. 2004;24:1665–1670
  45. Pucciarelli S, Codello L, Rosato A, Del Bianco P, Vecchiato G, Lise M. Effect of antiadhesive agents on peritoneal carcinomatosis in an experimental model. Br J Surg. 2003;90:66–71

☆ This work was supported by funds from Azione Biotech-Regione Veneto and the project SCINTIRAD, INFN, Italy.

PII: S0969-8051(09)00051-1

doi: 10.1016/j.nucmedbio.2009.02.005

Nuclear Medicine and Biology
Volume 36, Issue 5 , Pages 525-533 , July 2009

Article Tools

* Image Usage & Resolution